COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapies COBENFY has already been included...
- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China’s National...
Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...
– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2025: ...
- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with baseline brain metastases...
- Company to host conference call and webcast on November 6, 2025, at 8:00 a.m. ET (9:00 p.m. HKT)
- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (formerly called ZL-1310) as a promising next-generation, first- and best-in-class, Delta-like ligand (DLL3)-targeted...
New York, New York--(Newsfile Corp. - September 10, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Zai Lab Limited ("Zai Lab Limited") (NASDAQ: ZLAB) concerning possible...